Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2020-02-05

AUTHORS

Talha Badar, Nirav N. Shah

ABSTRACT

Opinion statementChimeric receptor antigen (CAR) T cells are an innovative cellular immunotherapeutic approach that involves genetic modification of T cells to express CAR targeting tumor antigen. Prior to the development of CAR-T, the only potential cure for patients with relapsed or refractory (RR) acute lymphoblastic leukemia (ALL) was allogeneic hematopoietic stem cell transplantation (HSCT). Several CAR-T cell products have been studied in prospective clinical trials which ultimately have resulted in the approval of one anti-CD19 CAR-T cell product in pediatric RR ALL: tisagenlecleucel (CD3ζ and 41BB). While some patients achieve durable responses with CAR-T, lack of response and relapse remains clinical challenges. Reasons for sub-optimal response include lack of CAR-T cell persistence and target antigen down-regulation. Future CARs are under development to improve long-term persistence and to be able to overcome resistance mechanisms associated with the disease and the hostile tumor microenvironment. With evolving understanding about CARs and new constructs under investigation, there is optimism that future products will improve the safety and efficacy from the current standard of care. More... »

PAGES

16

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11864-020-0706-6

DOI

http://dx.doi.org/10.1007/s11864-020-0706-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1124622999

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32025828


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, CD19", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antigens, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cost-Benefit Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Management", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genetic Engineering", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematopoietic Stem Cell Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy, Adoptive", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphocyte Depletion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Precursor Cell Lymphoblastic Leukemia-Lymphoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Antigen, T-Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Chimeric Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "T-Lymphocytes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Hematology and Oncology, Medical College of Wisconsin, 9200 W. Wisconsin Ave, 53226, Milwaukee, WI, USA", 
          "id": "http://www.grid.ac/institutes/grid.30760.32", 
          "name": [
            "Division of Hematology and Oncology, Medical College of Wisconsin, 9200 W. Wisconsin Ave, 53226, Milwaukee, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Badar", 
        "givenName": "Talha", 
        "id": "sg:person.01317726064.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317726064.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Hematology and Oncology, Medical College of Wisconsin, 9200 W. Wisconsin Ave, 53226, Milwaukee, WI, USA", 
          "id": "http://www.grid.ac/institutes/grid.30760.32", 
          "name": [
            "Division of Hematology and Oncology, Medical College of Wisconsin, 9200 W. Wisconsin Ave, 53226, Milwaukee, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shah", 
        "givenName": "Nirav N.", 
        "id": "sg:person.015270014615.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015270014615.39"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nm.1882", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051448639", 
          "https://doi.org/10.1038/nm.1882"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.4441", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092793846", 
          "https://doi.org/10.1038/nm.4441"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41591-019-0549-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1120764477", 
          "https://doi.org/10.1038/s41591-019-0549-5"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-02-05", 
    "datePublishedReg": "2020-02-05", 
    "description": "Opinion statementChimeric receptor antigen (CAR) T cells are an innovative cellular immunotherapeutic approach that involves genetic modification of T cells to express CAR targeting tumor antigen. Prior to the development of CAR-T, the only potential cure for patients with relapsed or refractory (RR) acute lymphoblastic leukemia (ALL) was allogeneic hematopoietic stem cell transplantation (HSCT). Several CAR-T cell products have been studied in prospective clinical trials which ultimately have resulted in the approval of one anti-CD19 CAR-T cell product in pediatric RR ALL: tisagenlecleucel (CD3\u03b6 and 41BB). While some patients achieve durable responses with CAR-T, lack of response and relapse remains clinical challenges. Reasons for sub-optimal response include lack of CAR-T cell persistence and target antigen down-regulation. Future CARs are under development to improve long-term persistence and to be able to overcome resistance mechanisms associated with the disease and the hostile tumor microenvironment. With evolving understanding about CARs and new constructs under investigation, there is optimism that future products will improve the safety and efficacy from the current standard of care.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11864-020-0706-6", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1022080", 
        "issn": [
          "1527-2729", 
          "1534-6277"
        ], 
        "name": "Current Treatment Options in Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "keywords": [
      "acute lymphoblastic leukemia", 
      "hematopoietic stem cell transplantation", 
      "CAR T-cell products", 
      "lymphoblastic leukemia", 
      "T cells", 
      "allogeneic hematopoietic stem cell transplantation", 
      "chimeric antigen receptor T-cell therapy", 
      "refractory acute lymphoblastic leukemia", 
      "CAR T cell persistence", 
      "CD19 CAR T-cell products", 
      "only potential cure", 
      "cell products", 
      "prospective clinical trials", 
      "stem cell transplantation", 
      "T-cell therapy", 
      "cellular immunotherapeutic approaches", 
      "hostile tumor microenvironment", 
      "sub-optimal response", 
      "lack of response", 
      "durable responses", 
      "immunotherapeutic approaches", 
      "cell transplantation", 
      "clinical trials", 
      "tumor antigens", 
      "clinical challenge", 
      "potential cure", 
      "cell persistence", 
      "tumor microenvironment", 
      "cell therapy", 
      "patients", 
      "current standard", 
      "leukemia", 
      "antigen", 
      "resistance mechanisms", 
      "cells", 
      "tisagenlecleucel", 
      "response", 
      "relapse", 
      "transplantation", 
      "long-term persistence", 
      "therapy", 
      "disease", 
      "trials", 
      "care", 
      "efficacy", 
      "cure", 
      "approval", 
      "microenvironment", 
      "persistence", 
      "lack", 
      "safety", 
      "RR", 
      "genetic modification", 
      "development", 
      "regulation", 
      "development of cars", 
      "mechanism", 
      "optimism", 
      "reasons", 
      "standards", 
      "investigation", 
      "products", 
      "challenges", 
      "understanding", 
      "constructs", 
      "modification", 
      "approach", 
      "new construct", 
      "cars", 
      "future products", 
      "future cars"
    ], 
    "name": "Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia", 
    "pagination": "16", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1124622999"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11864-020-0706-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32025828"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11864-020-0706-6", 
      "https://app.dimensions.ai/details/publication/pub.1124622999"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:47", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_855.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11864-020-0706-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11864-020-0706-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11864-020-0706-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11864-020-0706-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11864-020-0706-6'


 

This table displays all metadata directly associated to this object as RDF triples.

219 TRIPLES      21 PREDICATES      116 URIs      105 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11864-020-0706-6 schema:about N03815155e17245dc9ebb98c947d44315
2 N06b99b1c773f40589c56839dcb7e7bc5
3 N22999d12cbeb4595b25c3f0ad7613b6d
4 N2755c596520942d3bc66d7f23841c5d1
5 N45e46432e63a4f10a0bb48a42acf4c52
6 N606ca6785c034968b1aae793a89c2d06
7 N89c7833931f44737bd5058ca31d2b836
8 N8a6247243cde454280e675522b7534d7
9 N90e7f28262434125b1d7d8d6907e7772
10 N93422ec78396409ba78fc7eb780eb11b
11 Na0110a7bc9694092a14f99eab0022145
12 Nae1dac7bfd5440dfa97d55aeb4f2aaa7
13 Nbb104750e1a34105bcc18bdd21e8cac0
14 Nd2fa00d7b3d1446b82fc1b859e56f852
15 Ndd3cf33af0ca4b7d8c3c13c3531bfbd2
16 Ne6531c313f094e17a172b5b30c806d81
17 Nfc75eb113c014faba1b9b6c4c694d5a0
18 anzsrc-for:11
19 anzsrc-for:1107
20 schema:author N0b84fcda093b448fb005f085e3a70758
21 schema:citation sg:pub.10.1038/nm.1882
22 sg:pub.10.1038/nm.4441
23 sg:pub.10.1038/s41591-019-0549-5
24 schema:datePublished 2020-02-05
25 schema:datePublishedReg 2020-02-05
26 schema:description Opinion statementChimeric receptor antigen (CAR) T cells are an innovative cellular immunotherapeutic approach that involves genetic modification of T cells to express CAR targeting tumor antigen. Prior to the development of CAR-T, the only potential cure for patients with relapsed or refractory (RR) acute lymphoblastic leukemia (ALL) was allogeneic hematopoietic stem cell transplantation (HSCT). Several CAR-T cell products have been studied in prospective clinical trials which ultimately have resulted in the approval of one anti-CD19 CAR-T cell product in pediatric RR ALL: tisagenlecleucel (CD3ζ and 41BB). While some patients achieve durable responses with CAR-T, lack of response and relapse remains clinical challenges. Reasons for sub-optimal response include lack of CAR-T cell persistence and target antigen down-regulation. Future CARs are under development to improve long-term persistence and to be able to overcome resistance mechanisms associated with the disease and the hostile tumor microenvironment. With evolving understanding about CARs and new constructs under investigation, there is optimism that future products will improve the safety and efficacy from the current standard of care.
27 schema:genre article
28 schema:isAccessibleForFree false
29 schema:isPartOf Na688711c903d4e39a78e3c2dc717bc09
30 Nb2fad299c2d84a7b9a667de0f323d02b
31 sg:journal.1022080
32 schema:keywords CAR T cell persistence
33 CAR T-cell products
34 CD19 CAR T-cell products
35 RR
36 T cells
37 T-cell therapy
38 acute lymphoblastic leukemia
39 allogeneic hematopoietic stem cell transplantation
40 antigen
41 approach
42 approval
43 care
44 cars
45 cell persistence
46 cell products
47 cell therapy
48 cell transplantation
49 cells
50 cellular immunotherapeutic approaches
51 challenges
52 chimeric antigen receptor T-cell therapy
53 clinical challenge
54 clinical trials
55 constructs
56 cure
57 current standard
58 development
59 development of cars
60 disease
61 durable responses
62 efficacy
63 future cars
64 future products
65 genetic modification
66 hematopoietic stem cell transplantation
67 hostile tumor microenvironment
68 immunotherapeutic approaches
69 investigation
70 lack
71 lack of response
72 leukemia
73 long-term persistence
74 lymphoblastic leukemia
75 mechanism
76 microenvironment
77 modification
78 new construct
79 only potential cure
80 optimism
81 patients
82 persistence
83 potential cure
84 products
85 prospective clinical trials
86 reasons
87 refractory acute lymphoblastic leukemia
88 regulation
89 relapse
90 resistance mechanisms
91 response
92 safety
93 standards
94 stem cell transplantation
95 sub-optimal response
96 therapy
97 tisagenlecleucel
98 transplantation
99 trials
100 tumor antigens
101 tumor microenvironment
102 understanding
103 schema:name Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
104 schema:pagination 16
105 schema:productId N160969b2e7454343bfaaac1a9820e909
106 N751b1eaeceec43b793a2d36f52969115
107 Ne654bc7322344576ba901f75d219e706
108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1124622999
109 https://doi.org/10.1007/s11864-020-0706-6
110 schema:sdDatePublished 2022-10-01T06:47
111 schema:sdLicense https://scigraph.springernature.com/explorer/license/
112 schema:sdPublisher N0510f6bba00542de99edd0f89e6755f3
113 schema:url https://doi.org/10.1007/s11864-020-0706-6
114 sgo:license sg:explorer/license/
115 sgo:sdDataset articles
116 rdf:type schema:ScholarlyArticle
117 N03815155e17245dc9ebb98c947d44315 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Genetic Engineering
119 rdf:type schema:DefinedTerm
120 N0510f6bba00542de99edd0f89e6755f3 schema:name Springer Nature - SN SciGraph project
121 rdf:type schema:Organization
122 N06b99b1c773f40589c56839dcb7e7bc5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Treatment Outcome
124 rdf:type schema:DefinedTerm
125 N0b84fcda093b448fb005f085e3a70758 rdf:first sg:person.01317726064.40
126 rdf:rest Nd3694651ea444574bcd6125573a0d28c
127 N160969b2e7454343bfaaac1a9820e909 schema:name doi
128 schema:value 10.1007/s11864-020-0706-6
129 rdf:type schema:PropertyValue
130 N22999d12cbeb4595b25c3f0ad7613b6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name T-Lymphocytes
132 rdf:type schema:DefinedTerm
133 N2755c596520942d3bc66d7f23841c5d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Clinical Trials as Topic
135 rdf:type schema:DefinedTerm
136 N45e46432e63a4f10a0bb48a42acf4c52 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Cost-Benefit Analysis
138 rdf:type schema:DefinedTerm
139 N606ca6785c034968b1aae793a89c2d06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Receptors, Antigen, T-Cell
141 rdf:type schema:DefinedTerm
142 N751b1eaeceec43b793a2d36f52969115 schema:name dimensions_id
143 schema:value pub.1124622999
144 rdf:type schema:PropertyValue
145 N89c7833931f44737bd5058ca31d2b836 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Antigens, CD19
147 rdf:type schema:DefinedTerm
148 N8a6247243cde454280e675522b7534d7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Combined Modality Therapy
150 rdf:type schema:DefinedTerm
151 N90e7f28262434125b1d7d8d6907e7772 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Prognosis
153 rdf:type schema:DefinedTerm
154 N93422ec78396409ba78fc7eb780eb11b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Receptors, Chimeric Antigen
156 rdf:type schema:DefinedTerm
157 Na0110a7bc9694092a14f99eab0022145 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Hematopoietic Stem Cell Transplantation
159 rdf:type schema:DefinedTerm
160 Na688711c903d4e39a78e3c2dc717bc09 schema:volumeNumber 21
161 rdf:type schema:PublicationVolume
162 Nae1dac7bfd5440dfa97d55aeb4f2aaa7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Humans
164 rdf:type schema:DefinedTerm
165 Nb2fad299c2d84a7b9a667de0f323d02b schema:issueNumber 2
166 rdf:type schema:PublicationIssue
167 Nbb104750e1a34105bcc18bdd21e8cac0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Lymphocyte Depletion
169 rdf:type schema:DefinedTerm
170 Nd2fa00d7b3d1446b82fc1b859e56f852 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Disease Management
172 rdf:type schema:DefinedTerm
173 Nd3694651ea444574bcd6125573a0d28c rdf:first sg:person.015270014615.39
174 rdf:rest rdf:nil
175 Ndd3cf33af0ca4b7d8c3c13c3531bfbd2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Immunotherapy, Adoptive
177 rdf:type schema:DefinedTerm
178 Ne6531c313f094e17a172b5b30c806d81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Antigens, Neoplasm
180 rdf:type schema:DefinedTerm
181 Ne654bc7322344576ba901f75d219e706 schema:name pubmed_id
182 schema:value 32025828
183 rdf:type schema:PropertyValue
184 Nfc75eb113c014faba1b9b6c4c694d5a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Precursor Cell Lymphoblastic Leukemia-Lymphoma
186 rdf:type schema:DefinedTerm
187 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
188 schema:name Medical and Health Sciences
189 rdf:type schema:DefinedTerm
190 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
191 schema:name Immunology
192 rdf:type schema:DefinedTerm
193 sg:journal.1022080 schema:issn 1527-2729
194 1534-6277
195 schema:name Current Treatment Options in Oncology
196 schema:publisher Springer Nature
197 rdf:type schema:Periodical
198 sg:person.01317726064.40 schema:affiliation grid-institutes:grid.30760.32
199 schema:familyName Badar
200 schema:givenName Talha
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317726064.40
202 rdf:type schema:Person
203 sg:person.015270014615.39 schema:affiliation grid-institutes:grid.30760.32
204 schema:familyName Shah
205 schema:givenName Nirav N.
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015270014615.39
207 rdf:type schema:Person
208 sg:pub.10.1038/nm.1882 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051448639
209 https://doi.org/10.1038/nm.1882
210 rdf:type schema:CreativeWork
211 sg:pub.10.1038/nm.4441 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092793846
212 https://doi.org/10.1038/nm.4441
213 rdf:type schema:CreativeWork
214 sg:pub.10.1038/s41591-019-0549-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1120764477
215 https://doi.org/10.1038/s41591-019-0549-5
216 rdf:type schema:CreativeWork
217 grid-institutes:grid.30760.32 schema:alternateName Division of Hematology and Oncology, Medical College of Wisconsin, 9200 W. Wisconsin Ave, 53226, Milwaukee, WI, USA
218 schema:name Division of Hematology and Oncology, Medical College of Wisconsin, 9200 W. Wisconsin Ave, 53226, Milwaukee, WI, USA
219 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...